New Study: Recently Approved Drug-Resistant TB
Treatments Can Save National Governments up to
US$740 Million Annually
Published on: Tue, 22 Nov 2022
A new study published in PLOS Global Public Health found that the BPaLM/BPaL treatment regimen that will be included in World Health Organization (WHO) guidelines for the treatment of drug-resistant TB (DR-TB) could save governments up to US$740 million annually, enough monies to fund almost another year’s worth of DR-TB treatments for more than 400,000 people. The new study estimates that the cost of implementing this therapy is potentially 40-90% less expensive than current regimens.
Read more at the PLOS journal link or at this link: https://www.tballiance.org.za/